New Survey Finds U.S. Biotechs Advancing Treatments for Rare and Serious Diseases ...

A survey of U.S. biotech executives developing treatments for rare and serious diseases reveals a strong preference to run first-in-human clinical trials in the U.S. if FDA review processes were more consistent and timely, but current regulatory delays and costs are pushing companies to conduct trials overseas.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.